Buffet Breakfast

Medical Student Breakfast Meeting 

OPPA Annual Business Meeting and Installation of Officers

Welcome and Opening Remarks - Awais Aftab, MD and Karen Jacobs, DO, 2024 Program Co-Chairs

Research on Placebo Effect - Meaning, Medication and Health Equity

Kathryn Hall, PhD, MPH | Assistant Professor of Medicine, Part Time, Harvard Medical School, Associate Molecular Biologist, Brigham and Women’s Hospital

Placebos are simulacra of drugs, devices, or surgeries that lack the active compound, function, or procedure they are designed to simulate. Administration of these “inactive” treatments can have significant therapeutic benefits called placebo effects, which accounts for their use as controls in clinical trials as comparators for active drugs, devices, or surgical interventions. Key drivers of placebo effects include the patient’s expectation and conscious or subconscious conditioning. Psychological studies demonstrated that expectations are shaped by factors intrinsic to the patient, including their past experiences and core beliefs or mindsets, and extrinsic factors including environmental cues, clinical practice and information received about a treatment. Neuroimaging studies identified consistent changes in the brain in response to placebo treatment that suggest that placebo effects work by integrating incoming information about extrinsic factors with prior experience and mindsets to update expectations of treatment benefit. When expectations are negative, they can result in negative outcomes, termed, “nocebo effects.” In racially discordant clinical dyads, absence of placebogenic and presence of nocebogenic factors can erode treatment efficacy exacerbating health inequities. For many years, placebo effects were viewed as superfluous nuisance variables to be ignored, marginalized, and simply “controlled for” in clinical trials. Increasing failures in clinical trials due to high placebo response coupled with advances in placebo studies reinforce the value of understanding the mechanism of action of placebo effects and harnessing these effects in clinical care and clinical trials.

Integrated Mental Health and Suicide Prevention - What We Can Learn from the Veteran's Health Administration

Tamara Campbell, PsyD, MD | Executive Director, VA Office of Mental Health and Suicide Prevention, Veterans Health Administration, U.S. Department of Veterans Affairs

Break / Visit Exhibits

Psychosis, Coercion, and Civil Commitment: A Harm Reduction Approach

Nev Jones, PhD | Assistant Professor, University of Pittsburgh, School of Social Work

This presentation will review the potential harms of involuntary (or civil) psychiatric commitment and present a series of strategies aimed not at abolition or elimination but rather “harm reduction,” including in cases in which civil commitment is unavoidable in the contemporary practice and policy landscape.

Buffet Lunch / Visit Exhibits

Flash Talks

An integration of several five-minute Flash Talk presentations by resident/fellow members, from multiple training programs throughout Ohio, who will share novel research to improve quality of care in psychiatric treatment. Flash Talks are designed to quickly engage participants by sharing an idea, methodologies and outcomes in a clear and concise manner.

Human Trafficking, Healthcare, and Harm Reduction: Establishing a Standard of Care

Cheryl Wills, MD, DFAPA | Area 4 Trustee, APA Vice Chair for Equity, Diversity and Inclusion

Human trafficking is the second largest crime in the world and a public health crisis that affects at least 400,000 individuals in the U.S. and Worldwide. Healthcare is one of the only systems of care that trafficking victims interface with, yet health professionals fail to identify 88% of victims in the year before they are freed. Health professionals, boards, and legislators have been increasing training requirements for healthcare professionals so that they can become more proficient with identifying and assisting victims. This presentation will examine human trafficking, the process by which individuals are groomed for enslavement, how they present to hospitals and mental health professionals to help them.

Break / Visit Exhibits

Is a Psychedelic Revolution Coming to Psychiatry?

Brian Barnett, MD | Assistant Professor of Psychiatry, Clinical Director—Psychiatric Treatment Resistance Program, Cleveland Clinic

With the FDA currently reviewing a New Drug Application for MDMA for the treatment of post-traumatic stress disorder, psychedelic-assisted therapy appears poised to return to psychiatry by the end of the year. The aims of this talk are to help prepare attendees for this potentiality by reviewing the evidence base for psychedelic assisted therapy, discussing potential adverse effects of psychedelics, identifying populations for which risk of adverse effects is elevated, and providing an overview of anticipated implementation challenges for psychedelic assisted therapy within our healthcare system.

Poster Presentations

During this session, meeting attendees will have the opportunity to view 12 posters that ranked the highest based on scoring criteria in the poster competition organized by the Ohio Psychiatric Physicians Foundation for 2024.

RFM and ECP Social Gathering 

6 - 6:30 p.m.

OPPF Annual Meeting and Awards Presentation

6:30 - 8 p.m.

Dinner with Special Guest Speaker:

Brandon Edwin Chrostowski, Founder, President, and CEO of EDWINS Leadership & Restaurant

Saturday Evening Flyer

Sunday

9-10 a.m.

Perinatal Depression: Reviewing the Standard of Care and Exploring New Treatment Options

Danielle Johnson, MD, FAPA | Chief Medical Officer, Lindner Center of HOPE

An estimated one in seven women experience depression during or after birth but it is often undetected, untreated, or undertreated. This session will increase awareness of the screening tools, symptoms, and diagnosis of perinatal depression. The current standard of care, recent FDA approved medications for postpartum depression, and novel treatments will be discussed.

10-10:30 a.m.

Break / Visit Exhibits

10:30-11:30 a.m.

Cannabis Legalization in Ohio: Implications for the General Psychiatrist

David Gorelick, MD, PhD, DLFAPA, FASAM | Professor of Psychiatry, University of Maryland School of Medicine

This presentation reviews the implications for Ohio general psychiatrists of the December 2023 legalization of non-medical cannabis (not yet operational) on top of the 2016 legalization of medical cannabis, which became operational in January, 2019. It reviews the workings of the two current “Marijuana Control Programs” (including the role of physicians), the possible influence of legalization on the epidemiology of cannabis use and use disorder, the types of patients using medical or non-medical cannabis (or both) likely to be seen by a general psychiatrist, and recommended clinical approaches for managing such patients (including screening for cannabis use disorder and referral for appropriate treatment; understanding how cannabis use might influence treatment for other psychiatric disorders).

11:30-12:30 p.m.

Girls and Their Monsters: The Genain Quadruplets and Their Importance to our Understanding of Schizophrenia

Audrey Claire Farley, PhD | Professor of History, Mount St. Mary’s University

In 1954, researchers at the newly formed National Institute of Mental Health (NIMH) set out to study the genetics of schizophrenia. When they got word that 24-year-old identical quadruplets in Michigan had all been diagnosed with the mental illness, they could hardly believe it. Here seemed incontrovertible proof of hereditary transmission and, thus, a chance to bring international fame to their fledgling institution. In fact, the case of the pseudonymous Genain quadruplets was hardly so straightforward. Contrary to fawning media portrayals of a picture-perfect Christian family, the sisters had endured the stuff of nightmares. This presentation considers the quadruplets’ contributions to scientific research, as well to longstanding myths of white racial innocence. It further considers the role of the “psy” professions in obscuring racial, sexual, and religious trauma.

The Ohio Psychiatric Physicians Association’s Annual Psychiatric Update brings together psychiatrists and other mental health clinicians from all over Ohio to examine a broad array of topics of clinical interest and relevance to those who want to provide the best, evidence-based care possible for individuals with a mental illness, including substance use disorders. The objective is to educate and provide information on current research, cutting edge treatment options, advances in treatment in the area of psychopharmacology and more.

This is an excellent opportunity for companies to interact with and/or make products and services known to hundreds of psychiatrists, advanced practice nurses, physician assistants, psychologists, social workers, clinical counselors and other mental health professionals, including some of Ohio’s most prominent psychiatric physicians in leadership roles and academia.

(Click on image to download prospectus)

Complete Online Agreement

Letter To Prospective Exhibitors 2024

W9 - OPPA

Details About Meeting

THANK YOU 2024 SUPPORTERS!

Platinum Supporter

Silver Supporter

Bronze Supporter

THANK YOU 2024 EXHIBITORS!

Abbvie

Alkermes

APA Inc.

Axsome

Evoke Wellness

Indivior

Johnson & Johnson

Karuna Therapeutics

Oasis TMS

OhioHealth Hospital System

Ohio Professionals Health Program

OPPA/OPPF/OPPAC

Optimum TMS

Otsuka America Pharmaceuticals, Inc. - Digital Medicine

Otsuka Pharmaceutical

Otsuka - U.S. CNS

Professional Risk Management Services (PRMS)

Teva Medical Affairs

Teva Pharmaceuticals

The Recovery Village